Navigation Links
Genentech in Medical News

Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer

BASEL, Switzerland, March 6 /PRNewswire/ -- Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of Genentech (NYSE: DNA ) to US$ 93.00 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20,...

National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer

INDIANAPOLIS, LOS ANGELES, SOUTH SAN FRANCISCO, Calif., WASHINGTON, Feb. 19 /PRNewswire/ -- Tens of thousands of people surviving a cancer diagnosis may benefit from a new program being introduced today by a collaboration of health care providers, patient advocates, health benefit insurers and...

Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs

MELBOURNE, Australia, Feb. 27 /PRNewswire/ -- The Walter and Eliza Hall Institute of Medical Research (WEHI) announced today that Abbott, a global, broad-based, healthcare company, Genentech, a leading biotechnology company based in South San Francisco and WEHI have joined in a tripartite rese...

Roche Completes Acquisition of Genentech

BASEL, Switzerland and SAN FRANCISCO, March 26 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA ) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...veloped in collaboration with Genentech. The Phase 2 program continues to progress and the Company will be reviewing the complete NSCLC data set with genentech later this year. AMG 222: The Company has received results from a Phase 2a study of AMG 222 in patients with type 2 diabetes. The results s...

FDA Investigating Safety of Asthma Drug Xolair

... for the increase in heart attack and stroke seen among users of Xolair. genentech spokeswoman Tara Cooper said the preliminary study results are not sufficie...hives, and swelling of the mouth and throat. At that time, the FDA asked genentech to update the existing label warning and to provide a Patient Medication Gu...

TOPICA Elects G. Kirk Raab as Chairman of the Board

... to working with him." "Greg and I worked together successfully at genentech and Connetics Corporation, and I look forward to achieving a similar outcom...as president and chief executive officer of Genentech. He originally joined genentech in February 1985, as president and chief operating officer. Prior to joinin...

Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9

...ntion and potential treatments. Sponsored by genentech Oceanside, Survivor Beach is free and open to the ...0175 or visit www.cancer.ucsd.edu . About genentech Founded more than 30 years ago, genentech is a leading biotechnology company that discovers,...

New Report Just Published: World Telemedicine Market Report

...al Enters into Agreement with AmeriChoice II-30 Coventry Selects ICW for Telemonitoring Program II-31 InTouch Technologies Inks Agreement with genentech II-31 TeleHealth Services Takes Over Pathware's IHL Assets II-31 Retail Pharmacies and PBMs Merge Health Information Networks II-32 Virtua...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...lacel Signs Agreement to Acquire ALIGN Pharmaceuticals II-49 Biogen and genentech to Jointly Develop and Commercialize New Blood Cancer Drug II-49 Ae...cals to Acquire Somanta II-50 TopoTarget to Acquire Apoxis SA II-51 genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics II-51 ...
Genentech in Medical Technology

Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients

WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine strongly opposes the citizen petition filed by Genentech, Inc. on December 5, 2008, seeking to restrict the ability of laboratories to offer diagnostic tests to physicians and patients. The request threatens in...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines wit...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

...ww.ascenta.com . Taxotere(R) is a registered trademark of sanofi-aventis U.S. LLC Rituxan(R) is a registered trademark of Biogen Idec Inc. and genentech USA, Inc. Hycamtin(R) is a registered trademark of GlaxoSmithKline Temodar(R) is a registered trademark of Schering Corporation ...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

...ed sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is a...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... aspects of our technology with Dow Agrosciences in plant agriculture and Sigma-Aldrich Corporation in research reagents. We also have agreements with genentech and Pfizer in cell-line engineering. We plan to establish strategic partnerships around our therapeutic programs at points of value inflection and exp...

Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful

...ted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners-including majority ownership interests in genentech and Chugai-and has invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Roche employs about 79,000 people. Additional information i...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... sales of 9.3 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is avail...

FDA Approves First Hepatitis B Viral Load Test

...posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is avail...

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial

... look forward to continued progress." Tolerx and genentech entered into a collaboration in 2002 to develop an...noclonal antibodies. Pursuant to this arrangement, genentech has the right in all indications to develop, manuf...ne payments upon further successful development by genentech of the anti-CD4 monoclonal antibodies in autoimmun...

Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs

...posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is avail...
Genentech in Medical Definition

Personalized medicine

...c habits, earlier screening, exercise, prophylactic medications or surgery . Herceptin and Gleevec Two products, Herceptin supplied by genentech and Gleevec supplied by Novartis ,are prescribed on the basis of the outcome of a companion theranostic test. Herceptin treats a category of breas...
Genentech in Biological News

UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology

Bioinformatics researchers at the University of California, San Diego and Genentech have developed a new, quicker way to sequence monoclonal antibodies a process that is many times faster than the sequencing technology typically used by academic and industry researchers today. The breakthroug...

Engineer develops detergent to promote peripheral nerve healing

..., developed the detergent solution in her lab with Terry Hudson and Curt Deister, chemical engineering graduate students at the time, who are now with genentech in California and with AxoGen, respectively. "Surgeons are reporting some early successes," she says. These grafts are being used to treat peopl...

Leading scientist named new chair of Cell Biology at Yale

...t and immunologist who was chair and Sterling Professor of Cell Biology at the School of Medicine until 2007, when he joined the biotechnology company genentech as vice president for oncology research. Since Mellman's departure, James D. Jamieson, M.D., professor of cell biology and director of the medical sch...

National Lung Cancer Partnership and LUNGevity Foundation

...were created to advance research in basic lung cancer biology, risk assessment, prevention, detection, and response to treatment. With the support of genentech and our very generous donors, were able to offer researchers critical funding when choosing to investigate this deadly disease, said Regina Vidaver, e...

Clot-busting drug helps revive cardiac arrest patients

...and with standard therapy. Tenecteplase was developed and is marketed by genentech Inc. of South San Francisco as TNKase TM . genentech also provided support for the study. ...

Basic research leads to a novel cancer therapy

...ce from tumour cells, that could lead to targeted therapies against cancers. Already in the 1980s, cancer researcher Axel Ullrich, then a scientist at genentech (USA), working with colleagues in the UK and Israel, succeeded in describing the structure and function of a receptor for epidermal growth factor (EGF...
Genentech in Biological Technology

Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation

-- Roche intends to acquire all outstanding shares of Genentech for US$95.00 per share in cash -- Research and early development to operate as an independent center; South San Francisco site to become headquarters of combined U.S. commercial operations; Genentech's unique culture to be mainta...

Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash

BASEL, Switzerland, Jan. 30 /PRNewswire/ -- Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech at US$ 86.50 per share. Roche, which currently owns 55.8% of the Genentech outstanding shares, expects to commence the tender offe...

Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked

SEATTLE, Sept. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ), today announced that the Opposition Division (OD) of the European Patent Office (EPO) has revoked Genentech and Biogen Idec's European Patent 1176981, in its entirety. This patent was generally directed...

Roche Proposes to buy Full Stake in Genentech - Interview With Chairman

LONDON, July 21 /PRNewswire-FirstCall/ -- Roche, the healthcare company, announced today that it has proposed to acquire the outstanding publicly held interest in biotech company Genentech for US$89.00 per share in cash, or a total payment of approximately US$43.7bn to equity holders of Genent...

Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash

- Combination to enhance innovation by allowing for diversity of research approaches while also encouraging sharing of IP, technologies, partnerships and other key assets - Improved operational efficiency to result from reduced complexity, elimination of duplication...

ASCO Results: Oncologists Rank Genentech Number One

SAN MATEO, Calif., June 10 /PRNewswire/ -- When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail, Inc., a leader in oncology primary market research and influence network mapping solutions to t...

BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology

PRINCETON, N.J., March 3 /PRNewswire/ -- BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa's POTELLIGENT(R) Technology for the research and development of select antibodies for potential therapeutic applic...

Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production

Companies Agree to Expanded Access to ZFN Technology To Potentially Improve Protein Production RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it has entered into a second Research and License Agreement...

Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a New Report from Decision Resources WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, find...

Roche Completes Tender Offer for Genentech

BASEL, Switzerland, March 26 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech (NYSE: DNA ). The offer expired at midnight, New York ...
Genentech in Biological Definition

Biotechnology

...f the Human Genome Project Biotechnology firms The top 10 publicly-traded biotechnology companies, ranked by 2003 sales, are: Amgen genentech Serono Biogen Idec Chiron Genzyme MedImmune Gilead Sciences Cephalon Millennium Pharmaceuticals Biotechnology in fi...

Insulin

...antity for widespread clinical use, much reducing impurity reaction problems. Eli Lilly marketed the first such synthetic insulin, Humulin, in 1982 . genentech Inc developed the technique Lilly used. Modes of administration Unlike many medicines, insulin cannot be taken orally. It is treated in the ...
Other Tags
(Date:7/11/2014)... Volunteers from Scientology Churches and Missions ... drug education lectures, forums and conferences, information stands, sports ... the world. , Drug abuse is an international epidemic. ... abuse of alcohol and illicit drugs costs more than ... productivity and healthcare. , In the face of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... (July 10, 2014) Obese and overweight firefighters ... health care providers, according to new research from ... Houston (UTHealth). , National guidelines state that health ... importance of maintaining a healthy weight. Firefighters have ... the leading cause of line-of-duty deaths in firefighters. ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
Other Contents